Basic Information
| LncRNA/CircRNA Name | CASC9? |
| Synonyms | ESCCAL-1, ESSCAL1, LINC00981, linc-JPH1 |
| Region | GRCh38_8:75223404-75324741 |
| Ensemble | ENSG00000249395 |
| Refseq | NR_103848 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Luciferase reporter assay, other |
| Sample | plasma, HCC tissues and cell lines(HepG2, Hep3B, SNU398, SNU449, SNU182,SNU475 and PLC/PRF5) |
| Expression Pattern | up-regulated |
| Function Description | CASC9 and LUCAT1 were up-regulated in a subset of HCC-derived cell lines and in half of HCCs which displayed a lower recurrence after surgery. LUCAT1 and CASC9 silencing increased cell motility and invasion capability in HCC cells and influenced the EMT phenotype. LUCAT1 was demonstrated to directly sponge the onco-miR-181d-5p. Both LUCAT1 and CASC9 were secreted in exosomes, and higher circulating CASC9 levels were associated with tumor size and HCC recurrence after surgery, suggesting its potential usage as putative non-invasive prognostic biomarker of recurrence. |
| Pubmed ID | 30416681 |
| Year | 2018 |
| Title | LncRNAs as novel players in hepatocellular carcinoma recurrence. |
External Links
| Links for CASC9? | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |